OncoMatch/Clinical Trials/NCT06699602
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Is NCT06699602 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cemiplimab and Fianlimab for renal cell carcinoma.
Treatment: Cemiplimab · Fianlimab — The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nephrectomy is a safe and effective treatment approach and if there is a change in the size of the tumor following immunotherapy prior to planned surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Prior receipt of any systemic therapy for renal cell carcinoma.
Cannot have received: immune checkpoint inhibitor
Prior receipt of any immune checkpoint inhibitor therapy for any indication.
Lab requirements
Blood counts
ANC ≥ 1500/μL (no G-CSF within 2 weeks); WBC ≥ 2500/μL and ≤ 15,000/μL (no G-CSF); absolute lymphocyte count ≥ 500/μL; platelet count ≥ 100,000/μL (no transfusion within 2 weeks); hemoglobin ≥ 9.0 g/dL (no transfusion within 2 weeks)
Kidney function
Creatinine ≤ 2.0 x ULN or eGFR ≥ 40 mL/min using CKD-EPI formula
Liver function
ALT, AST, and ALP ≤ 3 X ULN; ALP ≤ 5 x ULN if patient has documented bone metastases; serum bilirubin ≤ 1.5 x ULN (≤ 2 x ULN if Gilbert disease)
Patients must have adequate organ and bone marrow function, defined by the following laboratory results obtained within 14 days prior to the first study treatment: ... (see full criteria for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06699602 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages